Jiangsu Theravac Bio-pharmaceutical

Jiangsu Theravac Bio-pharmaceutical is a clinical-stage biotechnology company based in China that specializes in the research, development, and commercialization of innovative recombinant protein vaccines. The company focuses on addressing significant unmet medical needs in infectious diseases, particularly those caused by multi-drug resistant bacteria. Its lead candidate is a recombinant Staphylococcus aureus vaccine, which has progressed into late-stage clinical trials. Theravac leverages proprietary protein engineering and adjuvant technologies to enhance the immunogenicity and safety of its vaccine candidates. The company aims to provide effective prophylactic solutions for hospital-acquired infections and other prevalent bacterial pathogens.